ES2231159T3 - Composiciones terapeuticas que contienen analogos de glutation. - Google Patents

Composiciones terapeuticas que contienen analogos de glutation.

Info

Publication number
ES2231159T3
ES2231159T3 ES00908420T ES00908420T ES2231159T3 ES 2231159 T3 ES2231159 T3 ES 2231159T3 ES 00908420 T ES00908420 T ES 00908420T ES 00908420 T ES00908420 T ES 00908420T ES 2231159 T3 ES2231159 T3 ES 2231159T3
Authority
ES
Spain
Prior art keywords
compound
lipid
formulation
parts
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00908420T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Redelmeier
Lawrence M. Kauvar
Robert T. Lum
Matthew H. Lyttle
Robert W. Macsata
Steven R. Schow
Hugo O. Villar
Michael R. Kozlowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of ES2231159T3 publication Critical patent/ES2231159T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES00908420T 1999-01-27 2000-01-27 Composiciones terapeuticas que contienen analogos de glutation. Expired - Lifetime ES2231159T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23853099A 1999-01-27 1999-01-27
US238530 1999-01-27

Publications (1)

Publication Number Publication Date
ES2231159T3 true ES2231159T3 (es) 2005-05-16

Family

ID=22898312

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00908420T Expired - Lifetime ES2231159T3 (es) 1999-01-27 2000-01-27 Composiciones terapeuticas que contienen analogos de glutation.

Country Status (12)

Country Link
EP (1) EP1143992B1 (https=)
JP (2) JP2002535359A (https=)
KR (1) KR100750842B1 (https=)
CN (1) CN1185008C (https=)
AT (1) ATE286741T1 (https=)
AU (1) AU778340B2 (https=)
CA (1) CA2360795C (https=)
DE (1) DE60017359T2 (https=)
ES (1) ES2231159T3 (https=)
HK (1) HK1043310B (https=)
PT (1) PT1143992E (https=)
WO (1) WO2000044366A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW576838B (en) 1998-04-16 2004-02-21 Teijin Ltd Glutathione derivatives and application form thereof
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
BRPI0606520A2 (pt) * 2005-01-06 2009-06-30 Telik Inc tripeptìdeo e tetrapeptìdeo tioéteres
CN101434645B (zh) * 2008-12-24 2013-01-16 中国农业大学 一种合成寡肽及其用途
AU2012321104A1 (en) * 2011-12-02 2013-06-20 Telik, Inc. Amphorous ezatiostat ansolvate
CN108863888B (zh) * 2018-07-18 2021-10-12 吉尔生化（上海）有限公司 一种(s)-1-(叔丁氧羰基)-5-氧吡咯烷-2-羧酸乙酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786336A (en) * 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
JP3118869B2 (ja) * 1991-05-14 2000-12-18 ウェルファイド株式会社 プロスタグランジン類含有脂肪小体組成物
CA2087902C (en) * 1992-02-05 2006-10-17 Narendra Raghunathji Desai Liposome compositions of porphyrin photosensitizers
JP3383704B2 (ja) * 1993-04-02 2003-03-04 わかもと製薬株式会社 安定なリポソーム水分散液
JPH09504517A (ja) * 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション カンプトテシン処方物
JP2891883B2 (ja) * 1993-11-05 1999-05-17 学校法人近畿大学 抗白内障医薬組成物
JPH11507056A (ja) * 1995-06-07 1999-06-22 テラピン テクノロジーズ、インク． グルタチオンアナログの代謝的効果

Also Published As

Publication number Publication date
WO2000044366A2 (en) 2000-08-03
EP1143992A2 (en) 2001-10-17
DE60017359T2 (de) 2005-12-01
KR100750842B1 (ko) 2007-08-22
EP1143992B1 (en) 2005-01-12
ATE286741T1 (de) 2005-01-15
AU778340B2 (en) 2004-12-02
CN1185008C (zh) 2005-01-19
DE60017359D1 (de) 2005-02-17
PT1143992E (pt) 2005-05-31
HK1043310B (zh) 2005-10-07
WO2000044366A3 (en) 2000-12-21
CA2360795A1 (en) 2000-08-03
JP2007326877A (ja) 2007-12-20
AU2976700A (en) 2000-08-18
HK1043310A1 (en) 2002-09-13
CN1342084A (zh) 2002-03-27
JP2002535359A (ja) 2002-10-22
KR20010101775A (ko) 2001-11-14
CA2360795C (en) 2010-03-23

Similar Documents

Publication Publication Date Title
US7029695B2 (en) Therapeutic compositions containing glutathione analogs
ES2285753T3 (es) Composicion que forma una emulsion para un compuesto taxoide.
Yang et al. Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer
ES2657214T3 (es) Vehículos de fármacos
ES2295647T3 (es) Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
ES2385995B2 (es) Nanocápsulas con cubierta polimérica
JP3074733B2 (ja) 脂肪乳剤
MX2014002131A (es) Pre-concentrado lipidico de liberacion sostenida de una sustancia farmacologicamente activa y una composicion farmaceutica que comprende el mismo.
JP2009507049A (ja) リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤
ES2377352T3 (es) Nuevas composiciones a base de taxoides
CN115703713A (zh) 一种新型阳离子脂质化合物
WO2023024513A1 (zh) 新型阳离子脂质化合物
Sonali et al. A Review on Niosomes: Potential Vesicular Drug Delivery System.
ES2231159T3 (es) Composiciones terapeuticas que contienen analogos de glutation.
CN105072981B (zh) 用于激光诱导纳米微球释放内含物的组合物和方法
US20250032620A1 (en) Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
EP3727328A1 (en) Liposomes comprising sphingomyelin
Hu et al. Thioether choline phosphate liposomes for reactive oxygen species-trigger drug release
CN115120611B (zh) 一种no供体型胶束组合物及其制备方法与应用
ES2269200T3 (es) Formulacion de liposomas de dimaleato de 6,9-bis-((2-aminoetil)-amino)benzo(g)isoquinolin-5,10-diona.
CA3236290A1 (en) Formulated and/or co-formulated nanocarriers compositions containing immunogenic cell death (icd) inducing prodrugs useful in the treatment of cancer and methods thereof
WO2023024512A1 (zh) 新型阳离子脂质化合物
CN118324842A (zh) 地塞米松弱碱性衍生物及其制剂的制备及应用
CN103275178A (zh) 正十二酸-rgd-正十四醇介导利尼法尼靶向脂质体的制备及抗肿瘤活性评价
Gupta et al. Peptide and protein devlopment using lipid nanocarrier delivery system